Abstract: The present invention relates to methods and compositions for specifically and quantitatively detecting galectin-3 in a sample. Embodiments of the invention include a detection assay in which a capture binding moiety and a labeled binding moiety specifically recognize non-overlapping epitopes on the N-terminus of galectin-3. Further embodiments are directed to a method for establishing ranges of galectin-3 concentrations indicative of the presence and severity of heart failure in a subject and a method for predicting the clinical outcome of a subject based upon galectin-3 concentration.

Abstract: The present teachings relate to liquid pharmaceutical formulations of furosemide, where the pharmaceutical formulations include a molar excess of tris(hydroxymethyl)aminomethane to furosemide, have a pH in the range of 7 to 8.5, and a concentration of tris(hydroxymethyl)aminomethane greater than or equal to about 50 mM. The present teachings can improve the stability of liquid pharmaceutical formulations including furosemide and the suitability of such pharmaceutical formulations for subcutaneous administration or delivery.

Abstract: The invention provides methods, compositions, and kits using a galectin-3 inhibitor to prevent and treat fibrosis resulting from a coronavirus infection, such as fibrosis in a subject's lung resulting from a coronavirus 2 infection.

Abstract: The invention provides methods, compositions, and kits using a galectin-3 inhibitor to prevent and treat retinal nerve damage in a subject suffering from glaucoma.

Abstract: A pharmaceutical composition and a method of administering the pharmaceutical composition to a patient suffering from edema, heart failure, kidney or liver disease or having symptoms thereof are disclosed. The pharmaceutical composition includes furosemide, or a pharmaceutically acceptable salt, hydrate or ester thereof and a cyclodextrin.

Abstract: The present teachings relate to liquid pharmaceutical formulations of furosemide, where the pharmaceutical formulations include a molar excess of tris(hydroxymethyl)aminomethane to furosemide, have a pH in the range of 7 to 8.5, and a concentration of tris(hydroxymethyl)aminomethane greater than or equal to about 50 mM. The present teachings can improve the stability of liquid pharmaceutical formulations including furosemide and the suitability of such pharmaceutical formulations for subcutaneous administration or delivery.

Abstract: A pharmaceutical composition and a method of administering the pharmaceutical composition to a patient suffering from edema, heart failure, kidney or liver disease or having symptoms thereof are disclosed. The pharmaceutical composition includes torsemide, or a pharmaceutically acceptable salt, hydrate or ester thereof and a cyclodextrin.

Abstract: A pharmaceutical composition and a method of administering the pharmaceutical composition to a patient suffering from edema, heart failure, kidney or liver disease or having symptoms thereof are disclosed. The pharmaceutical composition includes furosemide, or a pharmaceutically acceptable salt, hydrate or ester thereof and a cyclodextrin.

Abstract: A pharmaceutical composition and a method of administering the pharmaceutical composition to a patient suffering from edema, heart failure, kidney or liver disease or having symptoms thereof is disclosed. The pharmaceutical composition includes furosemide, or a pharmaceutically acceptable salt, hydrate or ester thereof and tris(hydroxymethyl)aminomethane. The furosemide is present in the pharmaceutical composition at a concentration from about 10 mg/mL to about 30 mg/mL and the tris(hydroxymethyl)aminomethane is present at a concentration of less than or equal to 40 mM. The pH value of the pharmaceutical composition is maintained between about 8.0 and about 8.5 for parenteral administration.

Abstract: A therapeutic composition includes a polysaccharide, isolated from a member of the genus Cucurbita, e.g., pumpkin, having a backbone including alternating ?-L-rhamnosyl (?-L-Rhap) and ?-D-galactopyranosyluronic acid (?-D-GapA) residues, and a side chain attached to the backbone including ?-D-galactan (?-D-Galp), ?-L-arabinofuranosyl (?-L-Araf), or combinations thereof, and a pharmaceutically acceptable excipient. A ?-D-Galp side chain is attached to the backbone at the C-4 carbon of at least one ?-L-Rhap of the backbone. At least one ?-L-Araf is attached to the ?-D-Galp side chain. The ?-L-Araf is attached to the ?-D-Galp side chain via the C-3 carbon of the ?-D-Galp. The polysaccharide is effective for treating a galectin-3 dependent disorder by binding to the carbohydrate recognition domain of galectin-3, resulting in inhibition of galectin-3 activity.

Abstract: A pharmaceutical composition and a method of administering the pharmaceutical composition to a patient suffering from edema, heart failure, kidney or liver disease or having symptoms thereof are disclosed. The pharmaceutical composition includes furosemide, or a pharmaceutically acceptable salt, hydrate or ester thereof and a cyclodextrin.

Abstract: The present teachings relate to liquid pharmaceutical formulations of furosemide, where the pharmaceutical formulations include a molar excess of tris(hydroxymethyl)aminomethane to furosemide, have a pH in the range of 7 to 8.5, and a concentration of tris(hydroxymethyl)aminomethane greater than or equal to about 50 mM. The present teachings can improve the stability of liquid pharmaceutical formulations including furosemide and the suitability of such pharmaceutical formulations for subcutaneous administration or delivery.

Abstract: The present invention relates to methods and compositions for specifically and quantitatively detecting galectin-3 in a sample. Embodiments of the invention include a detection assay in which a capture binding moiety and a labeled binding moiety specifically recognize non-overlapping epitopes on the N-terminus of galectin-3. Further embodiments are directed to a method for establishing ranges of galectin-3 concentrations indicative of the presence and severity of heart failure in a subject and a method for predicting the clinical outcome of a subject based upon galectin-3 concentration.

Abstract: A method of treating a hormonal disorder associated with androgen deficiency is disclosed. The method includes administering a therapeutically effective dose of a composition having a GnRH agonist to a subject in need thereof. The therapeutically effective dose is sufficient to support a first flare of hormones. The method further includes allowing a time interval after the administration of the dose. The time interval is sufficient to support pituitary-gonadal axis recovery. The method further includes administering at least one subsequent dose of the composition to the subject after the time interval. The subsequent dose is sufficient to support a microflare of hormones that is less than, or equal to, a magnitude of the first microflare. Subsequent doses spaced by the time interval resulting in a repeat microflare sufficient to chronically elevate hormone levels and provide relief of signs or symptoms of androgen deficiency.

Abstract: Methods for the prevention or treatment of a galectin-3 mediated or dependent condition in a subject are provided. The methods include orally administering a first amount of a carbohydrate material to the subject and orally administering a second amount of a selected carbohydrate digesting enzyme to the subject. The methods further include enzymatically converting the carbohydrate material into one or more bioactive fragments and producing the one or more bioactive fragments in an amount sufficient to therapeutically inhibit galectin-3 in the subject.

Abstract: Methods for the prevention or treatment of a galectin-3 mediated or dependent condition in a subject are provided. The methods include orally administering a first amount of a carbohydrate material to the subject and orally administering a second amount of a pectinase-producing probiotic to the subject. The methods further include enzymatically converting the carbohydrate material into one or more bioactive fragments and producing the one or more bioactive fragments in an amount sufficient to therapeutically inhibit galectin-3 in the subject.

Abstract: The present teachings relate to liquid pharmaceutical formulations of furosemide, where the pharmaceutical formulations include a molar excess of tris(hydroxymethyl)aminomethane to furosemide, have a pH in the range of 7 to 8.5, and a concentration of tris(hydroxymethyl)aminomethane greater than or equal to about 50 mM. The present teachings can improve the stability of liquid pharmaceutical formulations including furosemide and the suitability of such pharmaceutical formulations for subcutaneous administration or delivery.

Abstract: The present teachings relate to liquid pharmaceutical formulations of furosemide, where the pharmaceutical formulations include a molar excess of tris(hydroxymethyl)aminomethane to furosemide, have a pH in the range of 7 to 8.5, and a concentration of tris(hydroxymethyl)aminomethane greater than or equal to about 50 mM. The present teachings can improve the stability of liquid pharmaceutical formulations including furosemide and the suitability of such pharmaceutical formulations for subcutaneous administration or delivery.

Abstract: The present teachings relate to liquid pharmaceutical formulations of furosemide, where the pharmaceutical formulations include a molar excess of tris(hydroxymethyl)aminomethane to furosemide, have a pH in the range of 7 to 8.5, and a concentration of tris(hydroxymethyl)aminomethane greater than or equal to about 50 mM. The present teachings can improve the stability of liquid pharmaceutical formulations including furosemide and the suitability of such pharmaceutical formulations for subcutaneous administration or delivery.

Abstract: The present invention relates to methods and compositions for specifically and quantitatively detecting galectin-3 in a sample. Embodiments of the invention include a detection assay in which a capture binding moiety and a labeled binding moiety specifically recognize non-overlapping epitopes on the N-terminus of galectin-3. Further embodiments are directed to a method for establishing ranges of galectin-3 concentrations indicative of the presence and severity of heart failure in a subject and a method for predicting the clinical outcome of a subject based upon galectin-3 concentration.